Abstract 13225: Which Oral Anti-Coagulant Do Patients Prefer for Stroke Prevention in Non-Valvular Atrial Fibrillation?
Introduction: There are various oral anticoagulants available for stroke prevention in patients suffering from non-valvular atrial fibrillation (NVAF) with some drug-related variations in clinical profile and non-clinical attributes. Patient preferences should be taken into account in anticoagulant prescription decisions.
Hypothesis: Patient valuation of different anticoagulant characteristics in stroke prevention allows for meaningful comparison of the non-VKA oral anticoagulants (NOACs; apixaban, dabigatran, edoxaban, rivaroxaban) and Vitamin K Antagonist (VKA, ie. warfarin).
Methods: Multi-criteria decision analysis was developed with 5 clinical and 3 non-clinical criteria. Criteria weights were defined using results from two discrete choice experiments (DCEs). The evaluation model contained more fine-grained events than the DCEs, and therefore preference weights from DCEs needed to be distributed to the evaluation criteria. The weights were distributed according to event fatality rates, which were obtained from the RE-LY trial that compared dabigatran to warfarin. An additive model was used to combine treatment performance with the weights to estimate the overall value of each oral anticoagulant. Probabilistic and structural sensitivity analyses were performed.
Results: Dabigatran obtained the highest overall value (see Figure: weighted contribution of different evaluation criteria to the overall value of five oral anticoagulants) and the highest first rank probability (88%) in the probabilistic sensitivity analysis. Rivaroxaban performed worse than the other NOACs, but better than VKA (both with 0% first rank probability). The results were insensitive to removing availability of reversal agent from the model.
Conclusions: Patient preferences on treatment characteristics allows to discriminate oral anticoagulants for stroke prevention in NVAF, with dabigatran ranking highest and warfarin lowest.
Author Disclosures: G.Y. Lip: Honoraria; Significant; Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-Sankyo. Consultant/Advisory Board; Significant; Bayer/Janssen, Astellas, Merck, Sanofi, BMS/Pfizer, Biotronik, Medtronic, Portola, Boehringer Ingelheim, Microlife and Daiichi-Sankyo. P. Verdecchia: Honoraria; Significant; Boehringer Ingelheim, Bayer, BMS-Pfizer and Daiichi-Sankyo. Consultant/Advisory Board; Significant; Boehringer Ingelheim. T. Tervonen: Employment; Significant; Evidera. A. Ustyugova: Employment; Significant; Boehringer Ingelheim. J. Heinrich-Nols: Employment; Significant; Boehringer Ingelheim. S. Gropper: Employment; Significant; Boehringer Ingelheim. R. Kwan: Employment; Significant; Boehringer Ingelheim. S. Sri Bhashyam: Employment; Significant; Evidera. K. Marsh: Employment; Significant; Evidera.
- © 2016 by American Heart Association, Inc.